CIK 0001728328
- Emerging growth company
InMed Pharmaceuticals Inc.
Sign in to watch- Ticker
- MTRI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- Phone
- +1 604-669-7207
- Business address
- C/O NORTON ROSE FULBRIGHT CANADA LLP, SUITE 1800 - 510 WEST GEORGIA STREET, VANCOUVER, British Columbia, Canada, V6B 0M3
- 4 Open-market buy 10% owner bought 91,101 shares at an average $1.30 ($118,076)
- S-4/A Deal Registration Statement - Business Combination
- 425 Deal Prospectus/Communication re Business Combination
- 10-K Report Annual Report
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 425 Deal Prospectus/Communication re Business Combination
- 425 Deal Prospectus/Communication re Business Combination
- 8-K Event Regulation FD disclosure · Other events
- 425 Deal Prospectus/Communication re Business Combination
- 4 Open-market buy 10% owner bought 1,000 shares at $1.56 ($1,555)
- 4 Open-market buy 10% owner bought 20,546 shares at $1.55 ($31,846)
- 425 Deal Prospectus/Communication re Business Combination
- 8-K Event Material agreement · Regulation FD disclosure
- 4 Open-market buy 10% owner bought 6,551 shares at an average $1.55 ($10,148)
- S-4 Deal Registration Statement - Business Combination
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 249,227 shares at an average $1.57 ($391,555)
- 3 Insider Initial Statement of Ownership
- 8-K Event Other events
- SCHEDULE 13G Stake Statement of Beneficial Ownership
Page 3 of 27 · 537 filings